MENLO PARK, Calif. –(BUSINESS WIRE)–Feb. 20, 2025– AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two